Literature DB >> 3108858

Short gene inversion involving two adjacent heavy chain joining minigenes and one heavy chain diversity minigene in the nonsecretor Sp2/0-Ag14 myeloma cell line.

Z Q Liu, A F Wu, T T Wu.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3108858      PMCID: PMC340890          DOI: 10.1093/nar/15.11.4688

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


× No keyword cloud information.
  3 in total

1.  A joining-diversity-joining complex generated by inversion mechanism and a variable-diversity complex in the beta-chain gene of the human T-cell receptor.

Authors:  K Ikuta; T Ogura; A Shimizu; T Honjo
Journal:  Nucleic Acids Res       Date:  1986-06-25       Impact factor: 16.971

2.  Direct evidence for chromosomal inversion during T-cell receptor beta-gene rearrangements.

Authors:  M Malissen; C McCoy; D Blanc; J Trucy; C Devaux; A M Schmitt-Verhulst; F Fitch; L Hood; B Malissen
Journal:  Nature       Date:  1986 Jan 2-8       Impact factor: 49.962

3.  Use of JH4 joining segment gene by an anti-arsonate antibody that bears the major A-strain cross-reactive idiotype but displays diminished antigen binding.

Authors:  C A Slaughter; D J Jeske; W A Kuziel; E C Milner; J D Capra
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

  3 in total
  3 in total

1.  RAG-1 and RAG-2 are not sufficient to direct all phases of immunoglobulin gene rearrangement in pre-B-cell lines.

Authors:  L C Wang; N Rosenberg
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

2.  A rapid and scalable method for selecting recombinant mouse monoclonal antibodies.

Authors:  Cécile Crosnier; Nicole Staudt; Gavin J Wright
Journal:  BMC Biol       Date:  2010-06-04       Impact factor: 7.431

3.  Novel rearrangements at the immunoglobulin D locus. Inversions and fusions add to IgH somatic diversity.

Authors:  K D Meek; C A Hasemann; J D Capra
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.